The Future of Nuclear Medicine
SHINE Medical Technologies, Inc. (SHINE) is an advanced manufacturing company that will produce medical isotopes used to diagnose and treat heart disease, cancer, and many other diseases. SHINE invented, patented and developed a novel system to manufacture the medical isotope molybdenum-99 (Mo-99, commonly known as “moly”), with procedures requiring Mo-99 representing a $30 billion end market worldwide.
SHINE’s proprietary technology combines the use of an accelerator and a re-usable liquid target solution to enable the Company to produce Mo-99 at a much lower cost than the nuclear reactors that currently produce Mo-99. SHINE has proven that its Mo-99 meets the current market standard. In addition, SHINE’s process aligns with U.S. national security and health priorities by using low-enriched uranium (LEU) to make Mo-99 versus the nuclear weapons-grade, highly-enriched uranium (HEU) used in most conventional production of Mo-99.
SHINE already has long-term supply contracts with two of the three North American Mo-99 distributors, GE Healthcare (GE) and Lantheus Medical Imaging, as well as HTA, the largest Chinese producer, and distributor of radiopharmaceuticals. The Company is headquartered in Janesville, Wisconsin and its production facility will be built just four miles away.
- Recent Developments
- Argonne National Laboratory independently produced Mo-99 using SHINE’s proprietary process
- GE tested SHINE’s product and verified it fully met GE’s quality standards and supply chain needs
- The Nuclear Regulatory Commission formally approved SHINE’s application to build a medical isotope production facility – the first permit of this type awarded in more than 50 years
- SHINE signed a long-term supply agreement with HTA, the largest Mo-99 distributor in China
- The DOE/NNSA awarded SHINE a $20.9 million Phase II Cooperative Agreement
Want more information?
Todd Asmuth, President